The present invention relates to devices for performing intravascular procedures. More particularly, the present invention relates to devices for adding support to a guidewire so that the guidewire may be passed through a chronic total occlusion.
The use of intravascular catheters has become an effective method for treating many types of vascular disease. In general, an intravascular catheter is inserted into the vascular system of the patient and navigated through the vasculature to a desired target site. Using this method, virtually any target site in the patient's vascular system may be accessed, including the coronary, cerebral, and peripheral vasculature. Examples of therapeutic purposes for intravascular catheters include percutaneous transluminal angioplasty (PTA) and percutaneous transluminal coronary angioplasty (PTCA).
Intravascular catheters are commonly used in conjunction with a guidewire. A guidewire may be advanced through the patient's vasculature until it has reached a target location. Once in place, a catheter may be threaded onto the guidewire and urged distally until the distal end of the catheter reaches a target location.
When in use, the guidewire enters the patient's vasculature at a convenient location and then is urged to a target region. The path taken by a catheter through the vascular system is often tortuous, requiring the guidewire to change direction frequently. In order for the guidewire to conform to a patient's tortuous vascular system, it is desirable that it be very flexible, particularly near the distal end.
The guidewire will often confront a stenosis when passing through the vasculature. In addition, the stenosis may completely block the vessel as is the case with a chronic total occlusion. The success of the procedure often depends on the ability to insert the guidewire through the chronic total occlusion.
The present invention pertains to a chronic total occlusion device that may add support to a guidewire so that the guidewire may pass through a chronic total occlusion. The chronic total occlusion device may comprise an outer tubular member having a proximal end, a distal end, and a lumen extending therethrough. The proximal end may be connectable to a manifold and the distal end may include a distal tip.
An inner tubular member may be disposed within the lumen. The inner tubular member may comprise a proximal end, a distal end, and an inner lumen extending therethrough. The inner lumen may be adapted so that a guidewire may be disposed therein.
An annular space may be formed between the outer tubular member and the inner tubular member. A stiffening member may be disposed within the annular space. The stiffening member may comprise a distal head and a proximal tail. The proximal tail may be more stiff than the distal head. In an exemplary embodiment, the stiffening member is movable relative to the outer tubular member. The manifold may comprise a means for controlling the stiffening member.
The outer tubular member may further comprise an expandable region. The expandable region may further comprise a first region and a second region. The first region may include a first outside diameter. The second region may include a second outside diameter that, when expanded, is generally smaller than the outside diameter of a typical angioplasty balloon. According to this embodiment, the stiffening member may comprise inflation medium, liquid, or gas. Additionally, the manifold may include an inflation medium pump capable of pumping the inflation medium into the expandable region so that the chronic total occlusion device may add stiffness to the guidewire, dilate the vessel, anchor the device, or center the guidewire.
The chronic total occlusion may further comprise a marker band. The marker band may be disposed proximal of the distal tip. Alternatively, the marker band may be disposed at the distal tip.
The following description should be read with reference to the drawings wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings illustrate example embodiments.
Chronic total occlusion device 16 may be used to stiffen guidewire 14 in conjunction with a number of medical procedures. Chronic total occlusion device 16 may be used with a device or method that utilizes an intravascular guidewire. For example, chronic total occlusion device 16 may be used during percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA), atherectomy, or other vascular procedures.
Outer tubular member 18 may be comprised of materials including, but not limited to, metals, stainless steel, nickel alloys, nickel-titanium alloys, nitinol, thermoplastics, high performance engineering resins, fluorinated ethylene propylene (FEP), polymer, polyethylene (PE), polypropylene (PP), polyvinylchloride (PVC), polyurethane, polytetrafluoroethylene (PTFE), polyether-ether ketone (PEEK), polyimide, polyamide, polyphenylene sulfide (PPS), polyphenylene oxide (PPO), polysufone, nylon, or perfluoro (propyl vinyl ether) (PFA), and combinations thereof.
Outer tubular member 18 may be subdivided into a proximal segment 26 and a distal segment 28. According to this embodiment, proximal segment 26 may be comprised of CRISTAMID® 11200, which is a semi-aromatic co-polyamide polymer commercially available from Atochem and is the subject of U.S. Pat. No. 4,898,896, hereby incorporated by reference. Distal segment 28 may be comprised of polyether block amide (PEBA). Polyether block amide is commercially available from Atochem Polymers of Birdsboro, Pa., under the trade name PEBAX®. Distal segment 28 may have increased flexibility relative to proximal segment 26.
Proximal end 20 may be connectable to a manifold 30. Proximal end 20 may be bonded to manifold 30 with an adhesive. Alternatively, proximal end 20 may further comprise a luer adapter that is connectable to manifold 30. Distal end 22 may include a distal tip 32 that may be tapered. In an exemplary embodiment, distal tip 32 may be comprised of Grilamid® (ELY 2694, a nylon 12 elastomer), which is commercially available from EMS-Chemie.
An inner tubular member 34 may be disposed within Lumen 24. Inner tubular member 34 may be generally coaxial with outer tubular member 18. Inner tubular member 34 may comprise a proximal end 36, a distal end 38, and an inner lumen 40 extending therethrough. Inner tubular member 34 may comprise an inner layer of high density polyethylene (HDPE, namely MARLEX® HHM 4903, commercially available from Phillips Petroleum), an outer layer of polyether block amide (PEBAX® 7233), and a tie-layer of PLEXAR® 3080 to adhere the layers. PLEXAR® is a known tie layer material that is a modified low density polyethylene, commercially available from Equistar Chemicals, LP. Inner layer 34 may be manufactured by coextrusion of the above materials. Alternatively, inner tubular member 34 may be comprised of materials similar to those disclosed above for outer tubular member 18.
Inner lumen 40 may be adapted so that guidewire 14 may be disposed therein. Inner lumen 40 has an inside diameter appropriate to accommodate multiple embodiments of guidewire 14 having differing outside diameters. For example, inner lumen 40 may accommodate guidewire 14 having an outside diameter less than about 0.038-0.008 inches. Alternatively, inner lumen 40 may accommodate guidewire 14 having an outside diameter less than about 0.014 inches. Inner lumeri 40 may further comprise a lubricious liner. The lubricious liner may comprise polytetrafluoroethylene.
Although inner lumen 40 may have an inside diameter of appropriate size for many embodiments of guidewire 14, alteration of the inside diameter of inner lumen 40 may occur while maintaining the generally small profile of chronic total occlusion device 16 and, thus, the ability of outer tubular member 18 to pass through tight stenotic vasculature. According to this embodiment, the outside diameter of outer tubular member 18 may be less than about 0.200-0.500 inches.
An annular space 42 may be formed between outer tubular member 18 and inner tubular member 34. A stiffening member 44 may be disposed within annular space 42. Stiffening member 44 may comprise a number of materials similar to those listed above including metals and polymers. In addition, stiffening member 44 may comprise a wire or stiffening sleeve.
Stiffening member 44 may further include a distal head 46 and a proximal tail 48. Proximal tail 48 may be more stiff than distal head 46. Stiffening member 44 may be movable relative to outer tubular member 18. Actuation of stiffening member 44 can, thus, vary the stiffness of chronic total occlusion device 16 along the length of outer tubular member 18. For example, actuation of stiffening member 44 may comprise moving distal head 46 toward distal end 22. Actuation may result in increased stiffness of chronic total occlusion device 16 near distal end 22. Increased stiffness may enable chronic total occlusion device 16 to provide stiffness support to guidewire 14 so that guidewire 14 may pass through chronic total occlusion 12.
Manifold 30 may further comprise means for controlling stiffening member 44. Means for controlling stiffening member 44 may include an access port to proximal tail 48. According to this embodiment, manifold 30 may comprise an opening that may allow a clinician to grasp and move proximal tail 48 relative to outer tubular member 18. Additional means for controlling stiffening member 44 may include a handle assembly comprising an actuation button, wheel, lever, or slidable object wherein actuation of the means for controlling stiffening member 44 substantially results in movement of stiffening member 44 relative to outer tubular member 18. Moreover, the coupling of proximal tail 48 to manifold 30 may add further support along the length of guidewire 14 during, for example, exchange of catheters over guidewire 14 and for exchange of guidewires.
In use, chronic total occlusion device 16 or alternates thereof may be used in multiple ways to add support to guidewire 14. For example, chronic total occlusion device may be passed over guidewire 14 if chronic total occlusion 12 is encountered while steering guidewire 14 through blood vessel 10. According to this embodiment, guidewire 14 may be steered through blood vessel 10 until encountering chronic total occlusion 12, chronic total occlusion device 16 may be passed over guidewire 14, and chronic total occlusion device 16 (with guidewire 14 disposed in inner lumen 40) may pass chronic total occlusion 12. During the step of encountering or passing chronic total occlusion 12, chronic total occlusion device 12 may pre-dilate blood vessel 10 which may aid further dilation, for example, by an angioplasty catheter or stent. If desired, chronic total occlusion device 14 may be withdrawn from guidewire 14 until a further chronic total occlusion is encountered. Further, an alternative embodiment of chronic total occlusion device 16 comprises a single-operator-exchange catheter including a proximal guidewire port proximate distal end 22. The inclusion of the port may facilitate easier exchange of catheters along guidewire 14.
Alternatively, guidewire 14 may be disposed within inner lumen 40 while chronic total occlusion device 16 is steered through blood vessel 10. According to this embodiment, chronic total occlusion device 16 (with guidewire 14 disposed in inner lumen 40) may be steered through blood vessel 10 so as to more easily pass chronic total occlusion 12 when encountered. Similar to what is stated above, this method may be used in accordance with the single-operator-exchange embodiment disclosed above.
Marker band 150 may produce a relatively bright image on a fluoroscopy screen during a medical procedure. This relatively bright image may aid the user of chronic total occlusion device 16 in determining the location of distal end 22 of outer tubular member 18. Marker band 50 may comprise a number of radiopaque materials including, but not limited to, gold, platinum, and plastic material loaded with a radiopaque filler. Chronic total occlusion device 16 may further comprise additional marker bands or may comprise a marker band disposed at a different location. For example, chronic total occlusion device 16 may comprise a first marker band (e.g., marker band 150) a fixed distance from distal end 22 of outer tubular member 18. A second marker band may be disposed on outer tubular member 18 proximally a distance that is approximately equal to the distance the first marker band is from distal end 22.
Expandable region 352 may further comprise a first region 354 and a second region 356. First region 354 may include a first outside diameter 360. Second region 356 may include a second outside diameter 358 that, when expanded, may be generally smaller than the outside diameter of a typical angioplasty balloon. Moreover, first outside diameter 360 may be generally smaller than second outside diameter 358. Maintaining a generally smaller profile than a typical angioplasty balloon may allow chronic total occlusion device 316 to be steered through stenotic vasculature.
Stiffening member 344 may be disposed within expandable region 352. Stiffening member 344 may comprise inflation medium, liquid, or gas. According to this embodiment, stiffening member 344 can be moved along outer tubular member 318 to expandable region 352.
Annular space 342 may be in fluid communication with expandable region 352. Manifold 30 may further comprise means for controlling stiffening member 344. Means for controlling stiffening member 344 may include an inflation medium pump capable of pumping stiffening member 344 into expandable region 352. For example, manifold 30 may include an inflation medium pump suitable for pumping inflation fluid into expandable region 352.
In use, chronic total occlusion device 316 may be used substantially similar to chronic total occlusion device 16. Actuation of stiffening member 344 may comprise expanding expandable region 352 by passing stiffening member 344 into expandable region when guidewire 14 is disposed within inner tubular member 34. Actuation of stiffening member 344 may provide stiffening support to guidewire 14. Passing stiffening member 344 into expandable region may result in little or no expansion of expandable region 352. According to this embodiment, actuation of stiffening member 344 is understood to stiffen chronic total occlusion device 316 by adding tension to outer tubular member 318. Expandable region 352 may, thus, comprise materials that are substantially resistant to expansion.
Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
This is a continuation of U.S. application Ser. No. 09/918,245 filed on Jul. 30, 2001 now abandoned.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3472230 | Fogarty | Oct 1969 | A |
| 3592186 | Oster | Jul 1971 | A |
| 3683904 | Forster | Aug 1972 | A |
| 3889657 | Baumgarten | Jun 1975 | A |
| 3952747 | Kimmell, Jr. | Apr 1976 | A |
| 3996938 | Clark, III | Dec 1976 | A |
| 4046150 | Schwartz et al. | Sep 1977 | A |
| 4425908 | Simon | Jan 1984 | A |
| 4447227 | Kotsanis | May 1984 | A |
| 4580568 | Gianturco | Apr 1986 | A |
| 4590938 | Segura et al. | May 1986 | A |
| 4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
| 4631052 | Kensey | Dec 1986 | A |
| 4643184 | Mobin-Uddin | Feb 1987 | A |
| 4650466 | Luther | Mar 1987 | A |
| 4662885 | DiPisa, Jr. | May 1987 | A |
| 4705517 | DiPisa, Jr. | Nov 1987 | A |
| 4706671 | Weinrib | Nov 1987 | A |
| 4723549 | Wholey et al. | Feb 1988 | A |
| 4728319 | Masch | Mar 1988 | A |
| 4733665 | Palmaz | Mar 1988 | A |
| 4790812 | Hawkins, Jr. et al. | Dec 1988 | A |
| 4790813 | Kensey | Dec 1988 | A |
| 4794928 | Kletschka | Jan 1989 | A |
| 4794931 | Yock | Jan 1989 | A |
| 4800882 | Gianturco | Jan 1989 | A |
| 4807626 | McGirr | Feb 1989 | A |
| 4842579 | Shiber | Jun 1989 | A |
| 4857045 | Rydell | Aug 1989 | A |
| 4857046 | Stevens et al. | Aug 1989 | A |
| 4867157 | McGurk-Burleson et al. | Sep 1989 | A |
| 4873978 | Ginsburg | Oct 1989 | A |
| 4898575 | Fischell et al. | Feb 1990 | A |
| 4907336 | Gianturco | Mar 1990 | A |
| 4921478 | Solano et al. | May 1990 | A |
| 4921484 | Hillstead | May 1990 | A |
| 4926858 | Giffort, III et al. | May 1990 | A |
| 4950277 | Farr | Aug 1990 | A |
| 4955895 | Sugiyama et al. | Sep 1990 | A |
| 4957482 | Shiber | Sep 1990 | A |
| 4969891 | Gewertz | Nov 1990 | A |
| 4979951 | Simpson | Dec 1990 | A |
| 4986807 | Farr | Jan 1991 | A |
| 4998539 | Delsanti | Mar 1991 | A |
| 5002560 | Machold et al. | Mar 1991 | A |
| RE33569 | Gifford, III et al. | Apr 1991 | E |
| 5007896 | Shiber | Apr 1991 | A |
| 5007917 | Evans | Apr 1991 | A |
| 5011488 | Ginsburg | Apr 1991 | A |
| 5019088 | Farr | May 1991 | A |
| 5041126 | Gianturco | Aug 1991 | A |
| 5053008 | Bajaj | Oct 1991 | A |
| 5053044 | Mueller et al. | Oct 1991 | A |
| 5071407 | Termin et al. | Dec 1991 | A |
| 5071425 | Gifford, III et al. | Dec 1991 | A |
| 5085662 | Willard | Feb 1992 | A |
| 5087265 | Summers | Feb 1992 | A |
| 5100423 | Fearnot | Mar 1992 | A |
| 5100424 | Jang et al. | Mar 1992 | A |
| 5100425 | Fischell et al. | Mar 1992 | A |
| 5102415 | Guenther et al. | Apr 1992 | A |
| 5104399 | Lazarus | Apr 1992 | A |
| 5106376 | Mononen et al. | Apr 1992 | A |
| 5108419 | Reger et al. | Apr 1992 | A |
| 5116305 | Milder et al. | May 1992 | A |
| 5133733 | Rasmussen et al. | Jul 1992 | A |
| 5135531 | Shiber | Aug 1992 | A |
| 5152771 | Sabbaghian et al. | Oct 1992 | A |
| 5152777 | Goldberg et al. | Oct 1992 | A |
| 5160342 | Reger et al. | Nov 1992 | A |
| 5171233 | Amplatz et al. | Dec 1992 | A |
| 5190546 | Jervis | Mar 1993 | A |
| 5195955 | Don Michael | Mar 1993 | A |
| 5224953 | Morgentaler | Jul 1993 | A |
| 5231989 | Middleman et al. | Aug 1993 | A |
| 5306286 | Stack et al. | Apr 1994 | A |
| 5314444 | Gianturco | May 1994 | A |
| 5314472 | Fontaine | May 1994 | A |
| 5318576 | Plassche, Jr. et al. | Jun 1994 | A |
| 5329942 | Gunther et al. | Jul 1994 | A |
| 5330484 | Gunther et al. | Jul 1994 | A |
| 5330500 | Song | Jul 1994 | A |
| 5350398 | Pavcnik et al. | Sep 1994 | A |
| 5354310 | Garnic et al. | Oct 1994 | A |
| 5356423 | Tihon et al. | Oct 1994 | A |
| 5366464 | Belknap | Nov 1994 | A |
| 5366473 | Winston et al. | Nov 1994 | A |
| 5370657 | Irie | Dec 1994 | A |
| 5370683 | Fontaine | Dec 1994 | A |
| 5376100 | Lefebvre | Dec 1994 | A |
| 5383887 | Nadal | Jan 1995 | A |
| 5383892 | Cardon et al. | Jan 1995 | A |
| 5383926 | Lock et al. | Jan 1995 | A |
| 5387235 | Chuter | Feb 1995 | A |
| 5395349 | Quiachon et al. | Mar 1995 | A |
| 5397345 | Lazerus | Mar 1995 | A |
| 5405377 | Cragg | Apr 1995 | A |
| 5409454 | Fischell et al. | Apr 1995 | A |
| 5415630 | Gory et al. | May 1995 | A |
| 5419774 | Willard et al. | May 1995 | A |
| 5421832 | Lefebvre | Jun 1995 | A |
| 5423742 | Theron | Jun 1995 | A |
| 5423885 | Williams | Jun 1995 | A |
| 5425765 | Tiefenbrun et al. | Jun 1995 | A |
| 5443498 | Fontaine | Aug 1995 | A |
| 5449372 | Schmaltz et al. | Sep 1995 | A |
| 4842579 | Shiber | Oct 1995 | A |
| 5456667 | Ham et al. | Oct 1995 | A |
| 5462529 | Simpson et al. | Oct 1995 | A |
| 5476104 | Sheahon | Dec 1995 | A |
| 5484418 | Quiachon et al. | Jan 1996 | A |
| 5499973 | Saab | Mar 1996 | A |
| 5507767 | Maeda et al. | Apr 1996 | A |
| 5512044 | Duer | Apr 1996 | A |
| 5527354 | Fontaine et al. | Jun 1996 | A |
| 5536242 | Willard et al. | Jul 1996 | A |
| 5540707 | Ressemann et al. | Jul 1996 | A |
| 5549626 | Miller et al. | Aug 1996 | A |
| 5562724 | Vorwerk et al. | Oct 1996 | A |
| 5569274 | Rapacki et al. | Oct 1996 | A |
| 5569275 | Kotula et al. | Oct 1996 | A |
| 5634897 | Dance et al. | Jun 1997 | A |
| 5658296 | Bates et al. | Aug 1997 | A |
| 5662671 | Barbut et al. | Sep 1997 | A |
| 5669933 | Simon et al. | Sep 1997 | A |
| 5695519 | Summers et al. | Dec 1997 | A |
| 5709704 | Nott et al. | Jan 1998 | A |
| 5720764 | Naderlinger | Feb 1998 | A |
| 5728066 | Daneshvar | Mar 1998 | A |
| 5730734 | Adams et al. | Mar 1998 | A |
| 5746758 | Nordgren et al. | May 1998 | A |
| 5749848 | Jang et al. | May 1998 | A |
| 5769816 | Barbut et al. | Jun 1998 | A |
| 5779716 | Cano et al. | Jul 1998 | A |
| 5792300 | Inderbitzen et al. | Aug 1998 | A |
| 5795322 | Boudewijn | Aug 1998 | A |
| 5797952 | Klein | Aug 1998 | A |
| 5800457 | Gelbfish | Sep 1998 | A |
| 5800525 | Bachinski et al. | Sep 1998 | A |
| 5810874 | Lefebvre | Sep 1998 | A |
| 5814064 | Daniel et al. | Sep 1998 | A |
| 5817102 | Johnson et al. | Oct 1998 | A |
| 5827324 | Cassell et al. | Oct 1998 | A |
| 5833604 | Houser et al. | Nov 1998 | A |
| 5833644 | Zadno-Azizi et al. | Nov 1998 | A |
| 5833650 | Imran | Nov 1998 | A |
| 5846260 | Maahs | Dec 1998 | A |
| 5848964 | Samuels | Dec 1998 | A |
| 5876367 | Kaganov et al. | Mar 1999 | A |
| 5891112 | Samson | Apr 1999 | A |
| 5893867 | Bagaoisan et al. | Apr 1999 | A |
| 5895399 | Barbut et al. | Apr 1999 | A |
| 5902263 | Patterson et al. | May 1999 | A |
| 5906618 | Larson, III | May 1999 | A |
| 5908395 | Stalker et al. | Jun 1999 | A |
| 5908435 | Samuels | Jun 1999 | A |
| 5910154 | Tsugita et al. | Jun 1999 | A |
| 5911734 | Tsugita et al. | Jun 1999 | A |
| 5916193 | Stevens et al. | Jun 1999 | A |
| 5925016 | Chornenky et al. | Jul 1999 | A |
| 5925060 | Forber | Jul 1999 | A |
| 5925062 | Purdy | Jul 1999 | A |
| 5925063 | Khosravi | Jul 1999 | A |
| 5928203 | Davey et al. | Jul 1999 | A |
| 5928218 | Gelbfish | Jul 1999 | A |
| 5934284 | Plaia et al. | Aug 1999 | A |
| 5935139 | Bates | Aug 1999 | A |
| 5938645 | Gordon | Aug 1999 | A |
| 5941869 | Patterson et al. | Aug 1999 | A |
| 5941896 | Kerr | Aug 1999 | A |
| 5947995 | Samuels | Sep 1999 | A |
| 5951585 | Cathcart et al. | Sep 1999 | A |
| 5954745 | Gertler et al. | Sep 1999 | A |
| 5976172 | Homsma et al. | Nov 1999 | A |
| 5989210 | Morris et al. | Nov 1999 | A |
| 5989271 | Bonnette et al. | Nov 1999 | A |
| 5989281 | Barbut et al. | Nov 1999 | A |
| 5993469 | McKenzie et al. | Nov 1999 | A |
| 5997557 | Barbut et al. | Dec 1999 | A |
| 6001118 | Daniel et al. | Dec 1999 | A |
| 6007557 | Ambrisco et al. | Dec 1999 | A |
| 6010522 | Barbut et al. | Jan 2000 | A |
| 6013085 | Howard | Jan 2000 | A |
| 6027520 | Tsugita et al. | Feb 2000 | A |
| 6051014 | Jang | Apr 2000 | A |
| 6053932 | Daniel et al. | Apr 2000 | A |
| 6059814 | Ladd | May 2000 | A |
| 6068645 | Tu | May 2000 | A |
| 6086605 | Barbut et al. | Jul 2000 | A |
| 6129739 | Khosravi | Oct 2000 | A |
| 6142987 | Tsugita | Nov 2000 | A |
| 6152946 | Broome et al. | Nov 2000 | A |
| 6165200 | Tsugita et al. | Dec 2000 | A |
| 6168579 | Tsugita | Jan 2001 | B1 |
| 6171327 | Daniel et al. | Jan 2001 | B1 |
| 6179851 | Barbut et al. | Jan 2001 | B1 |
| 6179859 | Bates et al. | Jan 2001 | B1 |
| 6179861 | Khosravi et al. | Jan 2001 | B1 |
| 6203561 | Ramee et al. | Mar 2001 | B1 |
| 6214026 | Lepak et al. | Apr 2001 | B1 |
| 6368338 | Konya et al. | Apr 2002 | B1 |
| 6398798 | Selmon et al. | Jun 2002 | B2 |
| 6428552 | Sparks | Aug 2002 | B1 |
| 6500166 | Zadno Azizi et al. | Dec 2002 | B1 |
| 6506178 | Schubart et al. | Jan 2003 | B1 |
| 6508825 | Selmon et al. | Jan 2003 | B1 |
| 6511458 | Milo et al. | Jan 2003 | B2 |
| 6514217 | Selmon et al. | Feb 2003 | B1 |
| 6533753 | Haarstad et al. | Mar 2003 | B1 |
| 6544276 | Azizi | Apr 2003 | B1 |
| 6579302 | Duerig et al. | Jun 2003 | B2 |
| 6605062 | Hurley et al. | Aug 2003 | B1 |
| 20020077606 | Trotta | Jun 2002 | A1 |
| 20020091372 | Cragg et al. | Jul 2002 | A1 |
| 20020161353 | Kortelling | Oct 2002 | A1 |
| Number | Date | Country |
|---|---|---|
| 28 21 048 | Jul 1980 | DE |
| 34 17 738 | Nov 1985 | DE |
| 40 30 998 | Oct 1990 | DE |
| 0 200 688 | Nov 1986 | EP |
| 0 293 605 | Dec 1988 | EP |
| 0 411 118 | Feb 1991 | EP |
| 0 427 429 | May 1991 | EP |
| 0 437 121 | Jul 1991 | EP |
| 0 472 334 | Feb 1992 | EP |
| 0 472 368 | Feb 1992 | EP |
| 0 517 075 | Dec 1992 | EP |
| 0 533 511 | Mar 1993 | EP |
| 0 655 228 | Nov 1994 | EP |
| 0 686 379 | Jun 1995 | EP |
| 0 696 447 | Feb 1996 | EP |
| 0 737 450 | Oct 1996 | EP |
| 0 743 046 | Nov 1996 | EP |
| 0 759 287 | Feb 1997 | EP |
| 0 771 549 | May 1997 | EP |
| 0 784 988 | Jul 1997 | EP |
| 0 852 132 | Jul 1998 | EP |
| 0 934 729 | Aug 1999 | EP |
| 2 580 504 | Oct 1986 | FR |
| 2 643 250 | Aug 1990 | FR |
| 2 666 980 | Mar 1992 | FR |
| 2 768 326 | Mar 1999 | FR |
| 2 020 557 | Jan 1983 | GB |
| 8-187294 | Jul 1996 | JP |
| 764684 | Sep 1980 | SU |
| WO 9203097 | Mar 1992 | WO |
| WO 9414389 | Jul 1994 | WO |
| WO 9424946 | Nov 1994 | WO |
| WO 9601591 | Jan 1996 | WO |
| WO 9610375 | Apr 1996 | WO |
| WO 9619941 | Jul 1996 | WO |
| WO 9623441 | Aug 1996 | WO |
| WO 9633677 | Oct 1996 | WO |
| WO 9717100 | May 1997 | WO |
| WO 9727808 | Aug 1997 | WO |
| WO 9742879 | Nov 1997 | WO |
| WO 9802084 | Jan 1998 | WO |
| WO 9802112 | Jan 1998 | WO |
| WO 9823322 | Jun 1998 | WO |
| WO 9833443 | Aug 1998 | WO |
| WO 9834673 | Aug 1998 | WO |
| WO 9836786 | Aug 1998 | WO |
| WO 9838920 | Sep 1998 | WO |
| WO 9838929 | Sep 1998 | WO |
| WO 9839046 | Sep 1998 | WO |
| WO 9839053 | Sep 1998 | WO |
| WO 9846297 | Oct 1998 | WO |
| WO 9847447 | Oct 1998 | WO |
| WO 9849952 | Nov 1998 | WO |
| WO 9850103 | Nov 1998 | WO |
| WO 9851237 | Nov 1998 | WO |
| WO 9855175 | Dec 1998 | WO |
| WO 9909895 | Mar 1999 | WO |
| WO 9922673 | May 1999 | WO |
| WO 9923976 | May 1999 | WO |
| WO 9925252 | May 1999 | WO |
| WO 9930766 | Jun 1999 | WO |
| WO 9940964 | Aug 1999 | WO |
| WO 9942059 | Aug 1999 | WO |
| WO 9944510 | Sep 1999 | WO |
| WO 9944542 | Sep 1999 | WO |
| WO 9955236 | Nov 1999 | WO |
| WO 9958068 | Nov 1999 | WO |
| WO 0007655 | Feb 2000 | WO |
| WO 0009054 | Feb 2000 | WO |
| WO 0016705 | Mar 2000 | WO |
| WO 0049970 | Aug 2000 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20040073163 A1 | Apr 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09918245 | Jul 2001 | US |
| Child | 10704422 | US |